However, in U251-MG and T98-MG GBM cells, pretreatment of 2.5 to 10 μM AXT sensitized cells to TRAIL treatment in a statistically significant manner (p < 0.05) while it did not affect CRT-MG and U87-MG GBM cells. The gene discussed is TNFSF10; the disease is glioblastoma.